IRWD — Ironwood Pharmaceuticals Balance Sheet
0.000.00%
- $582.39m
- $1.03bn
- $351.41m
- 35
- 89
- 99
- 88
Annual balance sheet for Ironwood Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 363 | 620 | 656 | 92.2 | 88.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 122 | 114 | 115 | 129 | 81.9 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 496 | 745 | 781 | 233 | 182 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25.5 | 22.9 | 20.3 | 18.2 | 15.5 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 559 | 1,127 | 1,101 | 471 | 351 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 32.2 | 162 | 25.5 | 276 | 38.8 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 497 | 521 | 448 | 817 | 652 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 62.6 | 606 | 652 | -346 | -301 |
| Total Liabilities & Shareholders' Equity | 559 | 1,127 | 1,101 | 471 | 351 |
| Total Common Shares Outstanding |